Variable | Competing Risk HR (95% CI)†** |
---|---|
Female sex | 1.36 (0.75, 2.47) |
White | 1.60 (0.84, 3.05) |
Age at diagnosis ≤ 6 yrs | 1.30 (0.68, 2.49) |
JIA | 2.41 (1.28, 4.56) |
Oligo-JIA‡ | 5.93 (2.15, 16.36) |
ANA positive‡ | 1.67 (0.71, 3.98) |
Anterior uveitis | 2.52 (1.35, 4.69) |
Active uveitis at start§ | 1.00 (0.54, 1.85) |
Iris synechiae|| | 1.00 (0.46, 2.21) |
Pain/redness/photosensitivity‡ | 0.65 (0.31, 1.39) |
≥ 2 prior surgeries | 2.29 (0.70, 7.54) |
≥ 2 prior IMT | 0.46 (0.18, 1.22) |
MTX at start of anti-TNF | 1.47 (0.56, 3.89) |
IMT other than MTX at start | 0.62 (0.30, 1.30) |
Diagnosis to anti-TNF > 1 yr | 1.41 (0.73, 2.71) |
Anti-TNF | |
Etanercept | 1.00 (reference) |
Infliximab | 1.34 (0.53, 3.43) |
Adalimumab | 1.07 (0.22, 5.12) |
Monoclonal antibody anti-TNF¶ | 1.33 (0.52, 3.38) |
CHOP subcohort | 0.74 (0.35, 1.58) |
↵† A HR > 1 is favorable, representing a relatively higher incidence of treatment success. HR with 95% CI that does not cross 1 are in bold text.
↵** Proportional subhazards analysis, with drug discontinuation for failure or adverse reaction as a competing risk.
↵‡ Data are only available on subjects from CHOP.
↵§ Active uveitis, vs uveitis controlled but on corticosteroids, at the onset of anti-TNF.
↵|| Synechiae are adhesions between the iris and the lens (posterior) or cornea (anterior).
↵¶ Monoclonal anti-TNF (infliximab or adalimumab) vs etanercept. JIA: juvenile idiopathic arthritis; oligo-JIA: oligoarticular JIA; ANA: antinuclear antibodies; IMT: immunomodulatory therapy; MTX: methotrexate; anti-TNF: tumor necrosis factor-α inhibitor; CHOP: The Children’s Hospital of Philadelphia; SITE: the Systemic Immunosuppressive Therapy for Eye Disease Cohort Study.